Evaluation of Vaccination for Streptococcus Pneumoniae in Adults With an Episode of Invasive Pneumococcal Infection.

Invasive Pneumococcal Infection Clinical Trial

— pVax  

Official title:

Evaluation of Vaccination for Streptococcus Pneumoniae in Adults With an Episode of Invasive Pneumococcal Infection: a Retrospective Study in Two Lombardy Centers in the Pre-pandemic Phase From 2015 to 2019.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06334185
• Other study ID #: pVax
• Status: Not yet recruiting
• Start date: May 31, 2024
• Est. completion date: July 1, 2024

Study information

• Verified date: May 2024
• Source: Azienda Ospedaliera di Lecco
• Contact: Stefania Piconi, MD
• Phone: 0341-489890
• Email: s.piconi[@]asst-lecco.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Respiratory tract infections are among the leading causes of death worldwide and many of these infections are preventable through vaccination. One of the most important bacteria from an etiological and mortality point of view regarding respiratory and systemic infections is the gram-positive Streptococcus pneumoniae. Four types of vaccines are currently available for this pathogen: three pneumococcal conjugate vaccines (PCV13, PCV15, and PCV20) and one polysaccharide vaccine (PPSV23). In Italy, people over 65 years of age and people suffering from chronic pathologies with effects on the immune system would be advised to be vaccinated with the pneumococcal conjugate vaccine and with the polysaccharide vaccine as a second dose.

However, there are no data available in Italy on vaccination coverage in these population categories and above all the vaccination rates in patients who have a history of an episode of invasive pneumococcal infection are not known. The aim of the study is to measure how many patients are vaccinated for S. pneumoniae after hospitalization for a systemic pneumococcal infection in order to understand patients' awareness of preventing this infection after receiving a first diagnosis.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 320
• Est. completion date: July 1, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients over 18 years old;

• Patients hospitalized at the Manzoni Hospital in Lecco or at the San Raffaele Hospital in Milan with invasive pneumococcal infection in the period between 01/01/2015 and 31/12/2019;

• Presence of a positive culture test for S. pneumoniae on blood cultures and/or liquor;

• Patients whose discharge letter or clinical documentation relating to the infectious episode is available;

• Patients whose vaccination record can be consulted (on paper or on SIAVR) and whose vaccination history is available before and after hospitalization.

Exclusion Criteria:

• Patients with positive urinary antigen for S. pneumoniae as the only microbiological finding;

• Patients whose vaccination history or vaccination records are not available.

Related Conditions & MeSH terms

• Communicable Diseases
• Infections
• Invasive Pneumococcal Infection
• Pneumococcal Infections
• Pneumonia
• Pneumonia, Pneumococcal

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Azienda Ospedaliera di Lecco	IRCCS Ospedale San Raffaele

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of antipneumococcal vaccination in hospitalized patients for invasive pneumococcal infection between 2015 and 2019.		The information regarding vaccination after the infectious episode will be assessed by consulting the SIAVR portal or the vaccination booklet in a period between at least one month from discharge and up to 06/30/2023.
Secondary	Rate of pneumococcal serotype that caused the invasive infection in patients vaccinated prior to the infectious event		The information regarding vaccination after the infectious episode will be assessed by consulting the SIAVR portal or the vaccination booklet in a period between at least one month from discharge and up to 06/30/2023.